Goldman Sachs Group, Inc. (The) set a €97.00 ($112.79) target price on Fresenius Medical Care AG & Co. (Pref) (ETR:FME) in a research report released on Monday. The firm currently has a buy rating on the stock.

FME has been the subject of several other reports. Citigroup Inc. set a €92.00 ($106.98) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a buy rating in a report on Tuesday, August 8th. Deutsche Bank AG set a €85.00 ($98.84) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a neutral rating in a report on Wednesday, August 2nd. Kepler Capital Markets set a €95.00 ($110.47) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a buy rating in a report on Wednesday, August 2nd. Commerzbank Ag set a €88.00 ($102.33) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a neutral rating in a report on Tuesday, August 1st. Finally, Independent Research GmbH set a €88.00 ($102.33) price objective on Fresenius Medical Care AG & Co. (Pref) and gave the company a neutral rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Fresenius Medical Care AG & Co. (Pref) has an average rating of Buy and an average price target of €89.28 ($103.81).

Fresenius Medical Care AG & Co. (ETR FME) traded down €0.20 ($0.23) during mid-day trading on Monday, hitting €84.19 ($97.90). The company had a trading volume of 602,664 shares, compared to its average volume of 554,980. Fresenius Medical Care AG & Co. has a 12-month low of €70.69 ($82.20) and a 12-month high of €89.22 ($103.74).

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/07/fresenius-medical-care-ag-97-00-price-target-at-goldman-sachs-group-inc-the.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Stock Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related stocks with our FREE daily email newsletter.